Brown adipose tissue activity as a target for the treatment of obesity/insulin resistance by Anne-Laure Poher et al.
REVIEW ARTICLE
published: 30 January 2015
doi: 10.3389/fphys.2015.00004
Brown adipose tissue activity as a target for the treatment
of obesity/insulin resistance
Anne-Laure Poher1, Jordi Altirriba1, Christelle Veyrat-Durebex2 and Françoise Rohner-Jeanrenaud1*
1 Laboratory of Metabolism, Department of Internal Medicine Specialties, Faculty of Medicine, University of Geneva, Geneva, Switzerland
2 Department of Cell Physiology and Metabolism, University of Geneva, Geneva, Switzerland
Edited by:
Maria Moreno, University of Sannio,
Italy
Reviewed by:
Carola Waltraud Meyer,
Helmholtz-Zentrum Muenchen,
Germany
Florian Bolze, Technische Universität
München, Germany
*Correspondence:
Françoise Rohner-Jeanrenaud,
Laboratory of Metabolism,
Department of Internal Medicine
Specialties, Faculty of Medicine,
University of Geneva, 1 rue Michel
Servet, 1201 Geneva, Switzerland
e-mail: francoise.jeanrenaud@
unige.ch
Presence of brown adipose tissue (BAT), characterized by the expression of the
thermogenic uncoupling protein 1 (UCP1), has recently been described in adult humans.
UCP1 is expressed in classical brown adipocytes, as well as in “beige cells” in white
adipose tissue (WAT). The thermogenic activity of BAT is mainly controlled by the
sympathetic nervous system. Endocrine factors, such as fibroblast growth factor 21
(FGF21) and bone morphogenic protein factor-9 (BMP-9), predominantly produced in
the liver, were shown to lead to activation of BAT thermogenesis, as well as to
“browning” of WAT. This was also observed in response to irisin, a hormone secreted
by skeletal muscles. Different approaches were used to delineate the impact of UCP1
on insulin sensitivity. When studied under thermoneutral conditions, UCP1 knockout
mice exhibited markedly increased metabolic efficiency due to impaired thermogenesis.
The impact of UCP1 deletion on insulin sensitivity in these mice was not reported.
Conversely, several studies in both rodents and humans have shown that BAT activation
(by cold exposure, β3-agonist treatment, transplantation and others) improves glucose
tolerance and insulin sensitivity. Interestingly, similar results were obtained by adipose
tissue-specific overexpression of PR-domain-containing 16 (PRDM16) or BMP4 in mice.
The mediators of such beneficial effects seem to include FGF21, interleukin-6, BMP8B
and prostaglandin D2 synthase. Interestingly, some of these molecules can be secreted
by BAT itself, indicating the occurrence of autocrine effects. Stimulation of BAT activity
and/or recruitment of UCP1-positive cells are therefore relevant targets for the treatment
of obesity/type 2 diabetes in humans.
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INTRODUCTION
Obesity, well known to be associated with a number of comor-
bidities, including insulin resistance and type 2 diabetes, has
become a major public health problem in recent decades, and has
reached epidemic proportions, not only in high-income coun-
tries, but also in most middle-income societies. It is defined as
an accumulation of adipose tissue that is of sufficient magni-
tude to impair health (WHO, 2014). Excess weight is usually
defined by the body mass index or BMI. The normal BMI
range is 18.5–25 kg/m2, although the range may vary for dif-
ferent countries. Individuals with a BMI above 30 kg/m2 are
classified as obese; those with a BMI between 25 and 30 kg/m2
are considered to be overweight. In general, the term obesity
applies to both the obese and the overweight subjects. More than
the total body weight, the distribution of the stored fat is of
importance for the development of obesity and its comorbidi-
ties. Thus, central or visceral obesity, in which fat accumulates
in the trunk and in the abdominal cavity (in the mesentery
and around the viscera), is associated with a much higher risk
for several diseases than excess subcutaneous fat accumulation.
Obesity has profound effects on tissue insulin sensitivity, and
therefore on systemic glucose homeostasis. Insulin resistance is
present even in simple obesity, without hyperglycemia, indicat-
ing a fundamental abnormality of insulin signaling in states
of excess adipose tissue mass. The epidemiologic association
of obesity, particularly of the visceral type, with type 2 dia-
betes has been recognized for decades. According to the World
Health Organization, 347 millions of people are diabetic in the
world, and it is predicted that in 2030, diabetes will be the 7th
cause of death considering the worldwide population (WHO,
2014).
Although the pathogenesis of obesity is extremely complex
and is far from being unraveled, the key component of the
obesity epidemic is long-term dysregulation of energy balance,
comprising increased energy intake and/or reduced energy expen-
diture. Despite active research and impressive improvements in
the understanding of the regulation of energy balance, there are
only a very limited number of drugs that can be used for the
efficient treatment of obesity and its comorbidities. Targeting
specific components of the neuroendocrine regulation of energy
intake, such as leptin or hypothalamic neuropeptides, has disap-
pointingly revealed unsuccessful as yet. New alternatives focusing
on adipose tissue function could potentially be of therapeutic
relevance in the future.
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Two different types of adipose tissue have been described:
brown adipose tissue (BAT), composed mainly of brown
adipocytes, and white adipose tissue (WAT), defined by a major-
ity of white adipocytes, both tissues being able to accumulate
lipids in intracellular droplets. WAT is an energy-storing tissue
that has evolutionary enabled humans to survive for longer peri-
ods between meals, storing energy mainly as triglycerides and
releasing fatty acids during fasting periods. In recent times, when
food has become cheaper and more widely available, excessive
WAT storage contributed to the worldwide alarming develop-
ment of obesity mentioned above (World Health Organization,
2009). White adipocytes are composed of a large single, spheri-
cal lipid vacuole and a peripherally located nucleus, together with
few mitochondria. WAT has endocrine activity, secreting several
factors and hormones, such as leptin and adiponectin. Under cer-
tain conditions, another type of adipocytes, named brite or beige
cells, can be found dispersed within some of the WAT depots.
These cells, which will be discussed below, present a phenotype
with metabolic properties that are closest to brown than to white
adipocytes.
BAT consists in brown adipocytes, characterized by multiple,
small, multilocular lipid droplets with a central nucleus and a
high number of mitochondria. BAT is a highly vascularized tissue
innervated by the sympathetic nervous system. Themitochondria
of BAT are characterized by the presence of uncoupling protein-1
(UCP1) in the inner mitochondrial membrane. When activated,
this protein uncouples mitochondrial respiration from ATP syn-
thesis, resulting in heat production, a process that consumes
substantial amounts of fuels. BAT, the principal effector organ
of non-shivering thermogenesis (i.e., heat production that does
not involve skeletal muscle contraction), is present in most mam-
mals and its maturation in the perinatal period varies between
species, according to their developmental status at birth (Tews
and Wabitsch, 2011).
In humans, BAT develops in the fetus during gestation. Thus,
the amount of UCP1 increases during fetal development, peaks
at birth, before declining over the first 9 months (Lean et al.,
1986; Tews and Wabitsch, 2011). The notion that human BAT is
solely apparent during the neonatal stage prevailed for decades
(Heaton, 1972; Nedergaard et al., 2007). In 2009, functional
human BATwas identified in adults by a combination of CT scans
and fluorodeoxyglucose positron emission tomography (FDG-
PET) (Cypess et al., 2009; van Marken Lichtenbelt et al., 2009;
Virtanen et al., 2009). The areas in which BAT is observed in
adult humans include supraclavicular, neck, paravertebral, and
suprarenal sites (Nedergaard et al., 2007). Estimates of BAT mass
and activity from FDG-PET studies suggest that humans have,
on average, 50–80 g of BAT (Peirce et al., 2014). Quantitatively,
it was estimated that 50 g of BAT can burn as much as 20% of
daily energy intake (Rothwell and Stock, 1983). As an example,
in a subject with 63 g of supraclavicular BAT, it was calculated
that if the depot was fully activated, it would burn an amount
of energy equivalent to 4.1 kg of WAT (Virtanen et al., 2009). It
can therefore be concluded that, even though the BAT depots are
present in small amounts, the activated tissue has the potential to
substantially contribute to energy expenditure (Nedergaard et al.,
2007).
BAT activity is well known to mostly rely on lipid metabolism,
UCP1 being directly activated by fatty acids (Cannon and
Nedergaard, 2004). Along this line, it was recently demonstrated
that chronic activation of the β3 adrenoreceptor induces coupled
increases in lipolysis, de novo lipogenesis and fatty acid beta-
oxidation not only in white, but also in BAT (Mottillo et al., 2014).
Thus, the continuous cycling of triglyceride hydrolysis coupled
to resynthesis, which requires large amounts of ATP, could be
another important mechanism to increase thermogenesis in BAT,
in addition to the role of UCP1 activation in this process (Mottillo
et al., 2014). Similarly to what was proposed for skeletal muscle
(Dulloo et al., 2004), this may contribute to dissipate excess lipids
as occurs during prolonged stimulation of lipolysis (e.g., chronic
β3 adrenoreceptor treatment).
In addition to using lipids, BAT also displays a very high
rate of glucose uptake, particularly under sympathetic activa-
tion (Cannon and Nedergaard, 2004). Interestingly, BAT glucose
uptake is close to the values observed for metastasis in cancer in
humans (Aukema et al., 2010). This tissue also responds to insulin
with a 5-fold increase in glucose uptake, without any change in
blood flow (Orava et al., 2011), while under cold exposure, glu-
cose uptake increases by 12-folds, dissipating energy as a function
of increased blood flow (Orava et al., 2011). Regarding the fate of
glucose in brown adipocytes under anabolic conditions character-
ized by high insulin levels, it is essentially metabolized to provide
glycerol-3-phosphate for triglyceride synthesis or acetyl- CoA for
de novo fatty acid synthesis (Cannon and Nedergaard, 2004).
To investigate the role of BAT, of UCP1 in particular, stud-
ies were carried out in UCP1 knockout mice. Surprisingly, no
particular phenotype was noted in these mice when they were
kept at 23◦C, except for their increased cold sensitivity (Enerback
et al., 1997; Kontani et al., 2005). In contrast, when bred under
thermoneutral conditions (29◦C), UCP1 knockout mice exhib-
ited markedly enhanced metabolic efficiency due to impaired
thermogenesis (Feldmann et al., 2009).
Altogether, the existing literature suggests that BAT activation
is not only involved in non-shivering thermogenesis, but also
in the regulation of insulin-mediated glucose disposal. Whether
brown and brite adipocytes display some degree of specialization
with regard to these different functions has to be established. The
aims of this review are to describe some of the main factors regu-
lating UCP1 activity in brown and brite adipocytes, as well as to
discuss the potential role of UCP1 activation for the treatment of
insulin resistance and type 2 diabetes associated with obesity.
FACTORS AFFECTING BAT FUNCTION AND ENERGY
METABOLISM IMPROVE OVERALL METABOLISM
In rodents, brown adipocytes are found in discrete areas, such
as interscapular, cervical, peri-aortic, peri-renal, intercostal and
mediastinal depots (Cinti, 2001), which are referred to as “classi-
cal” BAT depots. In addition, brown adipocytes can be found scat-
tered in WAT, especially upon cold exposure (Young et al., 1984;
Guerra et al., 1998), treatment with β-adrenergic (Himms-Hagen
et al., 2000), or with peroxisome-proliferator-activated receptor-
γ (PPAR-γ) agonists (Petrovic et al., 2010). These brown-like
adipocytes have interchangeably been called “recruitable” (Tseng
et al., 2008; Schulz et al., 2013), “beige” (Ishibashi and Seale, 2010;
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Auffret et al., 2012; Wu et al., 2012), or “brite” (for brown to
white) (Petrovic et al., 2010; Gburcik et al., 2012) cells.
Lineage-tracing studies showed that brown adipocytes in clas-
sic BAT areas derive from myogenic factor 5 (Myf 5+)- pos-
itive progenitor cells, similarly to skeletal myocytes (Timmons
et al., 2007). In contrast, “brite” adipocytes have been shown to
originate from Myf-negative (Myf 5−) progenitor cells, much
like white adipocytes (Petrovic et al., 2010; Long et al., 2014).
Whether “brite” adipocytes descend from unique precursors, or
share progenitors with either white or classic brown adipocytes
still remains to be established (for rev., see Chechi et al., 2013).
Interestingly, the “browning” of WAT (i.e., increased proportion
of brown adipocytes) may also involve transdifferentiation of
white-to-brown adipose cells (Smorlesi et al., 2012; Frontini et al.,
2013), although this issue is still a matter of debate (Wu et al.,
2012).
Whatever their developmental origin, white, “brite” and
brown adipocytes seem to greatly differ in their function. As
mentioned above, BAT is the effector organ of non-shivering ther-
mogenesis (both cold and diet-induced) that, by utilizing large
quantities of glucose and lipids from the circulation, can promote
negative energy balance. Moreover, the role of BAT activation
appears to be broader than solely the promotion of negative
energy balance (for rev., see Peirce and Vidal-Puig, 2013). Indeed,
BAT is now known to exert anti-type 2 diabetic effects associ-
ated with improvments of dyslipidemia and insulin secretion as
well as decrease insulin resistance in type 2 diabetes (de Souza
et al., 1997; Liu et al., 1998; Frontini et al., 2013; Peirce and Vidal-
Puig, 2013). These effects are partly interrelated, but can also be
dissociated and exerted by different UCP1-expressing types of
adipocytes (i.e., brown and “brite” adipocytes). However, as these
different cells are often mixed, such as occurs for classical and
“brite” adipocytes in some human depots (Wu et al., 2012; Cypess
et al., 2013; Jespersen et al., 2013), only the use of specific cell
surface markers (i.e., ASC-1, PAT2, and P2RX5 for white, “brite”
and brown adipocytes, respectively) will allow for their identifi-
cation, as well as for the precise understanding of their respective
therapeutic properties (Ussar et al., 2014).
BAT activation by cold exposure, β3-agonist or thyroid
hormone treatment was shown to improve glucose tolerance
and insulin sensitivity (Cawthorne et al., 1984; Forest et al.,
1987; Peirce and Vidal-Puig, 2013). Similar observations were
obtained by adipose tissue-specific overexpression of PR-domain-
containing 16 (PRDM16) in mice. This Zinc-finger transcription
factor induces differentiation of brown adipocytes (Seale et al.,
2011). The main mediators of such beneficial effects seem to
include fibroblast growth factor 21 (FGF21), interleukin-6 (IL-6),
bone morphogenic proteins (BMPs) and prostaglandin D2 syn-
thase. Interestingly, some of these molecules, called batokines, can
be secreted by BAT itself, indicating the occurrence of autocrine
effects.
Fibroblast growth factor 21 is a member of the fibroblast
growth factor (FGF) family that acts as a hormone and that, in
contrast to other endocrine FGFs, is devoid of proliferative activ-
ity (Itoh, 2014). It is expressed in BAT andWAT, although its main
production site is the liver (Nishimura et al., 2000; Muise et al.,
2008; Schulz et al., 2013; Zafrir, 2013). Tissue-specific FGF21
regulation was shown to occur in response to chronic cold expo-
sure in mice (Fisher et al., 2012). Under this condition, FGF21
expression was indeed decreased in the liver, but enhanced in
BAT, as well as in WAT, where it acted to markedly increase
UCP1 expression and the “browning” of subcutaneous tissue
(Fisher et al., 2012). Interestingly, in humans, a mild cold expo-
sure (12 h to 19◦C) was recently shown to increase the diurnal
plasma FGF21 levels, with a positive correlation with the changes
in adipose tissue microdialysate glycerol and total energy expen-
diture (Lee et al., 2013). This suggested that FGF21 could play a
similar role in humans as in rodents in promoting cold-induced
metabolic changes (i.e., lipolysis and cold-induced thermogen-
esis). In adipose tissue, it appears that PPARγ transcriptionally
controls FGF21, which then acts as an autocrine or paracrine way
to increase PPARγ transcriptional activity in a feed-forward loop
system (Wang et al., 2008; Dutchak et al., 2012). FGF21 deficiency
in mice was shown to result in impaired ability to adapt to long-
term cold exposure with diminished “browning” of WAT (Fisher
et al., 2012). At the opposite, systemic administration of FGF21
in obese mice resulted in reduced adiposity, improved glycemic
control, as well as increased energy expenditure, as mentioned
by the authors (Coskun et al., 2008). Altogether, these obser-
vations suggest that FGF21 may be a key factor linking UCP1
expression to improved glucose metabolism. It may also exert
determinant developmental effects, given the observation that the
postnatal maturation of BAT appears to relate to the onset of feed-
ing and initiation of hepatic function, as mediated by the release
of FGF21 (Hondares et al., 2010). In addition, it was recently pro-
posed that FGF21 could act within the central nervous system,
both at the level of the hypothalamus and the hindbrain to pro-
mote a set of responses that occur during starvation (i.e. increase
in corticosterone levels, suppression of physical activity, alter-
ation in circadian behavior) (Bookout et al., 2013). This raises
the possibility that, in contrast to its beneficial effects on periph-
eral metabolism, FGF21 may exert deleterious effects by acting
centrally.
Interleukin-6 (IL-6), predominantly known as a pro-
inflammatory cytokine, is secreted by skeletal muscle (Pal et al.,
2014), helper T cells, as well as by WAT and BAT (Mohamed-Ali
et al., 1997; Cannon et al., 1998). Several studies implicated
IL-6 as a co-inducer of the development of obesity-associated
insulin resistance preceding the onset of type 2 diabetes (Pal
et al., 2014). This is in keeping with the observation of increased
plasma IL-6 levels in obese patients (Cottam et al., 2004). In
such patients, IL-6 is preferentially secreted from visceral rather
than from subcutaneous adipocytes and may participate in the
prevailing increase in sympathetic outflow by exerting central
effects (Wallenius et al., 2002; Fain et al., 2004). Paradoxically,
central IL-6 delivery was shown to suppress weight gain and
visceral obesity, without affecting food intake (Li et al., 2002).
The treatment also enhanced UCP1 protein levels in BAT, via
stimulation of the sympathetic nervous system (Li et al., 2002).
This was mediated by phosphorylation of the signal transducer
and activator of transcription 3 (pSTAT3). Interestingly, chronic
central IL-6 stimulation desensitized IL-6 signal transduction
characterized by reversal of elevated pSTAT3 levels (Li et al.,
2002). Such desensitization is likely occurring in situations of
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chronic elevation in IL-6 levels, such as occurs in human obesity.
It should be added that the understanding of the role of IL-6 is
more complex, as this cytokine is known to be secreted by skeletal
muscle in response to exercise, exerting insulin sensitizing effects
(Kelly et al., 2004; Petersen and Pedersen, 2005). Along this
line, it was recently shown that BAT transplantation into the
abdominal cavity of high fat diet-induced obese mice was able to
improve their glucose tolerance, increase their insulin sensitivity,
lower their body weight, decrease their fat mass and completely
reverse their insulin resistance (Stanford et al., 2013). BAT
transplantation also increased insulin-stimulated glucose uptake
in BAT, WAT, and heart, but not in skeletal muscle (Stanford
et al., 2013). Importantly, the improved metabolic profile was lost
when BAT used for transplantation came from IL-6 knockout
mice, clearly demonstrating that BAT-derived IL-6 is required
for the profound effects of BAT transplantation on glucose
homeostasis and insulin sensitivity (Stanford et al., 2013).
Apart from IL-6, another circulating factor, named irisin,
was shown to be produced by skeletal muscles during physi-
cal exercise in rodents (De Matteis et al., 2013). Irisin, obtained
by cleavage from the precursor protein, fibronectin type III
domain containing 5 (FNDC5), was described as promoting the
appearance/recruitment of “brite” cells in white adipose depots
(Bostrom et al., 2012; Lee et al., 2014a). However, the existence of
this protein and its role in humans is still a matter of debate (Elsen
et al., 2014a).
Thyroid hormones (THs) are well known mediators of over-
all energy expenditure (Klieverik et al., 2009). Treatment with
THs induces UCP1 expression in brown adipocytes in rats, fol-
lowing their binding to TH-responsive elements in the UCP1
promoter (Guerra et al., 1996). Type 2 iodothyronine deiodinase
(D2), responsible for the transformation of thyroxine (T4) to tri-
iodothyronine (T3), is also inducing UCP1 expression locally, in
BAT (de Jesus et al., 2001). Furthermore, treatment of brown
adipocytes and human skeletal myocytes with bile acids (BA)
were shown to increase D2 activity and oxygen consumption
via the activation of UCP1 (Watanabe et al., 2006). In both
rodents and humans, this BA-D2-UCP1 pathway appears to be
crucial for the fine-tuning of energy homeostasis, improving the
metabolic control (Watanabe et al., 2006). Thyroid receptors
(TRs) are composed of several isoforms that specifically regulate
UCP1 expression and thermogenesis. The α isoformwas shown to
regulate adaptive thermogenesis, whereas the β isoform appears
to modulate UCP1 expression, without increasing thermogene-
sis (Ribeiro et al., 2001). In humans, a unique patient suffering
from extreme diabetes due to a mutation in the insulin receptor
gene had to undergo total thyroidectomy because of the pres-
ence of a papillary carcinoma. Thirty months after the initial
treatment of the thyroid cancer (radioiodine and levothyrox-
ine), remarkable improvements in glycemia were noted and the
anti-diabetic treatment could even be discontinued. A PET/CT
study revealed the presence of BAT depots in the lower neck,
suprascapular, mediastinal, and thoracic paravertebral regions.
Interestingly, increased FDG uptake was also noted in the sub-
cutaneous fat, in particular in the pelvic area and over the lower
extremities. Overall, the sequence of events in this patient sug-
gests that the metabolic and trophic effects of THs on BAT may
play a critical role in non-insulin-mediated glucose utilization,
ultimately leading to near-normal glucose levels (Skarulis et al.,
2010).
Bonemorphogenic proteins (BMPs) are members of the trans-
forming growth factor β superfamily (TGF-β). They were orig-
inally thought to be factors inducing bone formation, but were
then described to be involved in the development and function of
many tissues, such as the intestine, brain andWAT (Hogan, 1996).
Some members of the BMP family were shown to play a role in
energy homeostasis and the early steps of adipogenesis, in partic-
ular. Among the 20 BMP family members, BMP-7 has been impli-
cated in the development of BAT, being able to drive the complete
brown fat differentiation program, including PRDM16 expres-
sion (Modica and Wolfrum, 2013). BMP-7 can also affect energy
homeostasis by acting on mature brown adipocytes, resulting in
the induction of UCP1, thereby enhancing thermogenesis. As it
is not expressed in mature brown adipocytes, BMP7 appears to
exert its action on BAT as an endocrine factor. In addition to its
effect on BAT, BMP-7 was also reported to induce the “brown-
ing” of WAT and to improve insulin sensitivity (Schulz et al.,
2011). Finally, several hypothalamic nuclei were shown to express
BMP-7, suggesting that it may regulate BAT function via a central
mechanism, also responsible for decreased food intake (Modica
and Wolfrum, 2013).
BMP8B, another member of the BMP family, was found to be
expressed in BAT, as well as in the hypothalamus (Contreras et al.,
2014). Central administration of BMP8B induced thermogenesis
and increased core temperature, leading to weight loss (Contreras
et al., 2014). This effect, exerted within the ventromedial hypotha-
lamus (VMH), was described as being AMPK-dependent, result-
ing in the activation of the sympathetic outlflow to BAT, without
any change in the feeding behavior (Whittle et al., 2012; Contreras
et al., 2014).
In contrast to BMP7 and BMP8B, BMP4 was shown to pro-
mote the differentiation of mesenchymal stem cells into white
adipocytes, inducing fat storage and decreasing energy expendi-
ture in rodents (Modica and Wolfrum, 2013; Contreras et al.,
2014). However, in primary human adipose stem cells, both
BMP4 and BMP7 induced a white-to-brown adipocyte transdif-
ferentiation (Elsen et al., 2014b), pointing to the occurrence of
different effects, depending on the model used for investigation.
Further studies are needed to clarify and strengthen the role of
BMP proteins in the regulation of BAT or “brite” cells and their
consequences on metabolic homeostasis.
Phosphatase and tensin homolog deleted on chromo-
some ten (PTEN), a well-known tumor suppressor is a
phosphatase that specifically catalyzes the dephosphory-
lation of phosphatidylinositol-3,4,5-triphosphate (PIP3),
in phosphatidylinositol-4,5-diphosphate PIP2 (Cantley
and Neel, 1999). This enzyme counteracts the action of
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K), resulting
in inhibition of the AKT signaling pathway involved in multiple
biological processes, including insulin action. Activation of AKT
is known to trigger a complex cascade of events that include
the inhibition of FOXO transcription factors (Ortega-Molina
et al., 2012). Interestingly, mice carrying additional copies of
Pten (Ptentg mice) are not only protected from cancer and
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exhibit extended longevity, but, according to the authors, they
also present enhanced energy expenditure that participates in
counteracting the development of obesity. This is related to lower
BAT levels of phosphorylated AKT and FOXO1, higher BAT
and WAT expression of UCP1, as well as of its transcriptional
regulator, PGC1-α (Ortega-Molina et al., 2012). In addition,
specific deletion of Pten in the liver in LPTENKO mice induces
a strong hepatic steatosis (Stiles et al., 2004; Peyrou et al., 2015),
but improves the overall insulin sensitivity, and decreases the
fat mass. “Browning” of WAT could be one of the mechanisms
underlying the increased insulin sensitivity of LPTENKO mice,
in keeping with the observation of increased WAT glucose uptake
(Peyrou et al., 2015). In humans, PTEN haploinsufficiency was
shown to have divergent effects, as they increase the risk of
obesity, while decreasing that of type 2 diabetes by markedly
improving insulin sensitivity (Pal et al., 2012). In a very recent
study, the grizzly bear was used as a hibernation model, in which
obesity is a natural adaptation to survive months of fasting
(Nelson et al., 2014). It was remarkably observed that prepara-
tion for hibernation was characterized by striking increases in
body weight and in fat mass. Animals were shown to exhibit
enhanced insulin sensitivity, while they become obese and to
develop insulin resistance a few weeks later, during hibernation,
to finally recover their insulin sensitivity upon awakening. The
modification of insulin sensitivity occurs via the effect of the
PTEN/AKT-mediated regulation of adipose tissue lipolysis.
These results support the notion that adipose tissue is very
insulin sensitive in the fed state, while being able to drive insulin
resistance in the fasting state, independently from insulin levels
(Nelson et al., 2014). In humans, the only physiological recovery
of insulin sensitivity after a period of insulin resistance, partially
due to an increase in food intake and lipogenesis, is observed in
women after pregnancy (Barbour et al., 2007).
The present knowledge on the impact of the main batokines,
as well as of the principal other UCP1 modulators on peripheral
metabolism is schematized by Figure 1.
IMPACT OF PERINATAL NUTRITIONAL CHANGES
Epidemiological evidence in humans strongly suggests that the
intrauterine and early postnatal environments have a significant
long-term influence on body weight and energy homeostasis in
offspring (for rev., see Breton, 2013). Thus, both maternal under-
feeding or overfeeding were reported to exert a predisposing effect
for the development of later obesity (Breton, 2013). Rodents are
commonly used to investigate the mechanisms underlying long-
term programming of energy balance in the offspring. High fat
feeding of pregnant or lactating mothers was shown to induce
glucose intolerance and the development of obesity in the progeny
during adult life (Bayol et al., 2008; Samuelsson et al., 2008). The
signals that mediate the effects of maternal metabolic disorders
in overfed offspring have not been fully identified. They include
hormones, such as insulin, leptin and glucocorticoids, proinflam-
matory cytokines, as well as complex epigenetic modifications
(Tamashiro and Moran, 2010; Lukaszewski et al., 2013).
In this context, the sheep appears to be a very good model,
because as for humans, the major source of BAT in the fetus
is around central organs and is replaced by WAT after birth,
whereas in rodents, the primary BAT depot is interscapular and
FIGURE 1 | Schematic representation of the main factors described in
the review, which modulate UCP1 activity. TL, T lymphocytes; SNS,
sympathetic nervous system. For other abbreviations, see text. Full lines
indicate stimulatory effects, whereas dotted lines represent inhibitory ones. ?
indicates the existence of conflicting data in the literature with regard to the
impact of the factor on UCP1 activity.
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it remains throughout life (Symonds et al., 2012). In sheep, the
mother’s diet during pregnancy determines the size of the pla-
centa and can affect both the BAT and WAT mass, depending
on the timing and the nature of the diet perturbation. In other
words, the respective growth of the BAT andWAT depots depends
on the maternal diet during gestation and it may be responsi-
ble for the development of obesity, insulin resistance and type
2 diabetes in the offspring, later in life (Symonds et al., 2012).
Gestational diabetes in humans is a situation of increased nutri-
ent supply that, together with the high maternal body mass index,
can be accompanied by enhanced birth-weight and adverse long-
term metabolic consequences, as described by the World Health
Organization (2003), as well as in several publications (Larsson
et al., 1986; Dabelea et al., 2000; Singh et al., 2006). However, in a
recent study, the role of diabetes during gestation on such adverse
long-termmetabolic consequences has been seriously questioned,
as they seem to relate more on known confounders, such as the
BMI of either one of the parents (Donovan and Cundy, 2014).
Among the regulators that may link the maternal diet dur-
ing gestation with the metabolic outcome of the offspring,
leptin is one of the main candidates. It is a well-known hor-
mone increasing BAT activity and inducing “browning” of WAT
via activation of the sympathetic nervous system and result-
ing increased β3 adrenoceptor signaling (Haynes et al., 1997;
Commins et al., 2000). Rodent models of leptin deficiency exhibit
marked decreases in BAT thermogenic capacity, as well as activity
(Ueno et al., 1998). Moreover, it was shown that leptin injection
in the early stage of life in lambs decreases UCP1 expression in
BAT, but improves thermoregulation, suggesting a particular role
of leptin at such a stage in life in large mammals (Mostyn et al.,
2002). Another study revealed that the ability of leptin to increase
the metabolic rate early in life is independent from its anorectic
action (Mistry et al., 1999).
No data are available as yet with regard to the impact of early
leptin administration on the subsequent “browning” of WAT
and the related regulation of glucose metabolism, as well as the
response to hypercaloric diets later in life in the offspring.
ATTEMPTS AT STIMULATING BAT FUNCTION IN HUMANS
With regard to the relationship between BAT and body weight
in humans, an inverse correlation between BMI and the amount
of BAT was described, already 5 years ago (Cypess et al., 2009;
van Marken Lichtenbelt et al., 2009). In addition, more recent
studies indicated that, compared to individuals without BAT,
the BAT-positive subjects were younger, had lower body mass
index, fasting insulin, insulin resistance, but a greater level of
high-density lipoprotein cholesterol (Zhang et al., 2013). During
acute cold exposure, BAT was shown as a significant independent
determinant of plasma glucose and HbA1c levels (Matsushita
et al., 2014). A parallel increase in BAT activity and cold-induced
energy expenditure was also observed in response to acute cold
exposure in subjects with low BAT activity, demonstrating the
possible occurrence of BAT recruitment in humans (Yoneshiro
et al., 2013). Very recently, chronic cold acclimation in human
subjects was reported to increase the volume of metabolically
active BAT, increasing its oxidative capacity, therefore its contri-
bution to cold-induced thermogenesis (Blondin et al., 2014). In
another study, the cold-induced increase in thermogenesis was
accompanied by a decrease in body weight, mainly affecting the
fat mass compartment (Yoneshiro et al., 2013). Cold-acclimation
was also shown to increase diet-induced thermogenesis and
postprandial insulin sensitivity, without impacting cold-induced
thermogenesis (Lee et al., 2014b). These results are in keeping
with data showing a physiological role of BAT in whole-body
energy expenditure, glucose homeostasis, and insulin sensitivity
in humans during prolonged cold exposure (Chondronikola et al.,
2014).
Much more work is needed to identify other ways than cold
exposure to increase BAT activity in obese subjects. To this end,
one of the very useful tools is the use of rodent strains with
different sensitivities to diet-induced obesity and insulin resis-
tance. Indeed, resistance to the development of obesity has at
least partly been attributed to elevated recruitment of brown
adipocytes in skeletal muscle orWAT (Guerra et al., 1998; Almind
et al., 2007; Veyrat-Durebex et al., 2009; Harms and Seale, 2013).
These studies are highly therapeutically relevant, as BAT activa-
tion in overweight or obese subjects will activate thermogenesis
and dissipate heat, while at the same time improving glucose
metabolism and insulin resistance.
It should be added at that point that, although β3 adrenocep-
tors are expressed in humans (for rev., see Mund and Frishman,
2013) and β3 agonists are potent UCP1 activators in rodents, the
molecules which are active in rodents cannot be used in humans
due to inter-species differences. This should be solved in the
future by the identification of selective human β3 agonists (Mund
and Frishman, 2013; Bordicchia et al., 2014).
CONCLUSION
To conclude, UCP1 is an excellent target to struggle diabetes and
decrease body fat mass, improving whole metabolism. Indeed,
it negatively regulates the energy balance by increasing energy
expenditure. It also secretes several batokines, allowing for inter-
organ communication. Finally, it is easily inducible, such as dur-
ing mild cold exposure with resulting beneficial effects. Finding
a molecule with as much efficiency as the β3 agonist in rodents,
would be of considerable therapeutic relevance for the treatment
of obesity, insulin resistance and type 2 diabetes in humans.
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